Drugs against leishmaniasis: A synergy of technology and partnerships

Trends in Parasitology

Volumn 20, Issue 2, 2004, Pages 73-76

  Davis, Antony J ^a   Murray, Henry W ^b   Handman, Emanuela ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIPROTOZOAL AGENT; FUNGICIDE; IMMUNOMODULATING AGENT; NELFINAVIR; ZANAMIVIR;

CELLULAR IMMUNITY; CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE SEQUENCE; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; KNOCKOUT GENE; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARASITE VIRULENCE; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS; PROTOZOA;

EID: 1642432131     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.11.006     Document Type: Article

References (34)

1. Reithinger R., et al. Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan. Emerg. Infect. Dis. 9:2003;727-729.
2. Seaman J., et al. The epidemic of visceral leishmaniasis in western upper Nile, southern Sudan: course and impact from 1984 to 1994. Int. J. Epidemiol. 25:1996;862-871.
3. Zijlstra E.E., el-Hassan A.M. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 95:(Suppl. 1):2001;S27-S58.
4. Herwaldt B.L. Leishmaniasis. Lancet. 354:1999;1191-1199.
5. Yardley V., Croft S.L. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents. 13:2000;243-248.
6. Murray H.W. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45:2001;2185-2197.
7. Croft S., et al. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:2003;502-508.
8. Garrett L. The next epidemic. Mann J.M., et al. AIDS in the World. 1992;825-839 Harvard University Press.
9. Murray H.W., et al. Immunoenhancement combined with amphotericin B as treatment in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 47:2003;2513-2517.
10. Pritchard J.F., et al. Making better drugs: decision gates in non-clinical drug development. Nat. Rev. Drug Discov. 2:2003;542-553.
11. Smith C. Drug target validation: hitting the target. Nature. 2003;422. 341, 343, 345.
12. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964.
13. Bleicher K.H., et al. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2:2003;369-378.
14. von Itzstein M., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
15. Bente M., et al. Developmentally induced changes of the proteome in the protozoan parasite Leishmania donovani. Proteomics. 3:2003;1811-1829.
16. El Fakhry Y., et al. A proteomic approach to identify developmentally regulated proteins in Leishmania infantum. Proteomics. 2:2002;1007-1017.
17. Acestor N., et al. Establishing two-dimensional gels for the analysis of Leishmania proteomes. Proteomics. 2:2002;877-879.
18. Drummelsmith J., et al. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol. Cell. Proteomics. 2:2003;146-155.
19. Walters W.P., Namchuk M. Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov. 2:2003;259-266.
20. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26.
21. Walters W.P., et al. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 3:1999;384-387.
22. Halperin I., et al. Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins. 47:2002;409-443.
23. Blundell T.L., et al. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1:2002;45-54.
24. Greer J., et al. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem. 37:1994;1035-1054.
25. Bajorath J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 1:2002;882-894.
26. Bressi J.C., et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J. Med. Chem. 44:2001;2080-2093.
27. Davis A.M., et al. Application and limitations of x-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. Engl. 42:2003;2718-2736.
28. Masihi K.N. Concepts of immunostimulation to increase antiparasitic drug action. Parasitol. Res. 90:(Suppl. 2):2003;S97-S104.
29. Murray H.W., et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:2002;6284-6293.
30. Murray H.W., et al. Modulation of T cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 71:2003;6453-6462.
31. Buates S., Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. 179:1999;1485-1494.
32. Arevalo I., et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33:2001;1847-1851.
33. Walsh C. Where will new antibiotics come from? Nat. Rev. Microbiol. 1:2003;65-70.
34. Clarke T. Drug companies snub antibiotics as pipeline threatens to run dry. Nature. 425:2003;225.